Exelixis, Inc.
Exelixis, Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
1 of 3 strong
The short version
- CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. - Exelixis reiterated full-year 2026 financial guidance (page 3), indicating confidence in stable or growing earnings. - Strong current growth with first quarter 2026 CABOMETYX U.S.
From Exelixis, Inc.'s Q2 FY26 earnings-call transcript · updated 30 May 2026.
Revenue & Sales Performance
- CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. net product revenues grew 8% YoY to $555 million.
- CABOMETYX TRx volume increased 14% in Q1 2026 vs Q1 2025, outpacing market growth (7%).
- CABOMETYX gained 3 share points from 44% to 47% in the oral TKI market basket in Q1 2026.
- Highest number of new patient starts ever for CABOMETYX in Q1 2026, indicating strong momentum.
- Expansion of GI sales team to grow CABOMETYX's neuroendocrine tumor market share, especially in community settings.
- Full launch preparation underway for ZANZA (zanzalintinib) in colorectal cancer later in 2026, representing a $1.5 billion market opportunity.
2 more points from Exelixis, Inc.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Exelixis, Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Exelixis is allocating capital across three key areas: R&D investments, business development (BD) opportunities, and share repurchases.
- The company maintains a financially strong position with significant cash flows, enabling balanced funding of these priorities.
- They prioritize R&D spend continuously, funding projects that demonstrate potential, while BD activities are overseen by senior leadership for strategic opportunities.
- Share repurchases are ongoing, with recent repurchases totaling approximately $430.8 million in Q1 2026 and a new $750 million stock repurchase plan authorized in May 2026, expiring December 2027.
2 more points from Exelixis, Inc.'s call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Exelixis, Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Exelixis, Inc.'s call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
- BridgeBio Pharma, Inc. (Q2 FY26)
BridgeBio Pharma, Inc. Q2 FY26 quarterly results analysis. Attruby franchise shows durable growth with a 24% increase in net sales from Q4 and 392% YoY growth i
Arthneeti Pro · Annual
Exelixis, Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Exelixis, Inc. Q2 FY26 results?
- CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. - Exelixis reiterated full-year 2026 financial guidance (page 3), indicating confidence in stable or growing earnings. - Strong current growth with first quarter 2026 CABOMETYX U.S.
What is Exelixis, Inc. share price analysis?
Exelixis, Inc. currently shows a below-average growth signal. The stock trades at a P/E of 16.5 with a market cap of $12,932. Investors should review the full earnings analysis for detailed insights.
Is Exelixis, Inc. planning capital expenditure?
- Exelixis is allocating capital across three key areas: R&D investments, business development (BD) opportunities, and share repurchases.
Keep Exelixis, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.